Company intelligence / Profile preview
CollPlant Biotechnologies
- Ownership
- Public · CLGN
- Employees
- ~57
- Development stage
- Other
Overview
CollPlant's key regenerative breast implant program has shown promising early animal data with evidence of tissue regeneration and neovascularization, as well as a promising safety profile. The dermal filler program partnered with AbbVie has entered the clinical phase with interim human data being reviewed by AbbVie as of 2025. Preclinical data supports safety and efficacy for wound healing and tendon healing products.[7][6][2]
- Therapeutic areas
- Women's HealthDermatologyRheumatologyOther
- Modalities
- Recombinant proteinBiologicBioinkPhotocurable hydrogelMedical device
- Industry
- Biotech
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on CollPlant Biotechnologies.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CollPlant Biotechnologies.